MAD2L1

Across TCGA pan-cancer cohorts, MAD2L1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAD2L1 data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAD2L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAD2L1 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where MAD2L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.733	0.955	<.001	59	view →
LUAD	OS	Median	All	0.931	0.989	.012	12	view →
PDAC	OS	Median	III,IV	0.259	0.606	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAD2L1–CCRCC (OS)

Open the CCRCC breakdown →